Clinical Management and Therapeutic Approach for Zoonotic Hepeviruses

WG2 focuses on advancing clinical management and therapeutic strategies for zoonotic hepeviruses through harmonized standards and collaborative research. The group aims to establish robust and comparable clinical trial frameworks, standardize outcome measurements, and support the identification and development of antiviral therapies.

Key activities include developing standardized guidelines for clinical trial design and outcome assessment, reviewing pharmaceutical and preclinical data to identify promising antiviral compounds (supported by AI-based approaches), and selecting and validating biomarkers to monitor disease progression and treatment response. In addition, WG2 will organize a dedicated workshop to strengthen clinical expertise, particularly among early-career researchers, and promote best practices in patient management.